We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · January 21, 2021

Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients With Chronic HFrEF

European Heart Journal

 

Additional Info

European Heart Journal
Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients With Chronic Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
Eur Heart J 2021 Jan 11;[EPub Ahead of Print], M Packer, SD Anker, J Butler, et al

Further Reading